HLA-E and Ewing sarcoma: Experiments using immunodeficient mice engrafted with Ewing’s sarcoma or osteosarcoma cell lines transduced with HLA-E found that the majority of immunodeficient mice receiving NKG2Anull NK cell infusions achieved long-term survival, with the median overall survival exceeding 269 days following Ewing’s sarcoma injection and median survival not reached after 60 days follow-up for osteosarcoma injection (106).